The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / CMS Implements Part B Modifiers for Biosimilars

CMS Implements Part B Modifiers for Biosimilars

September 20, 2017 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

With the advent of biosimilars to the marketplace, the Centers for Medicare and Medicaid Services (CMS) now requires modifiers to identify the manufacturer of a biosimilar/biological product on Part B claims. Modifiers were put in place to provide the CMS with the necessary data needed to track claims payments, as well as the ability to understand the use of the biosimilar drugs.

You Might Also Like
  • Coding Corner Answer: A Quiz on Modifiers
  • New HCPCS Modifiers Replace -59 on January 1, 2015
  • Coding Corner Question: A Quiz on Modifiers
Also By This Author
  • Practice Page: Cross-Train Staff to Improve Practice Management

Every quarter, the CMS will update the assignment of modifiers to specific Healthcare Common Procedure Coding System (HCPCS) codes. If a new biosimilar becomes available, and one or more modifiers are already associated with its assigned HCPCS code, then a Not Otherwise Classified (NOC) code without a modifier may be used to bill for the new biosimilar product. For more information, visit Part B Biosimilar Biological Product Payment and Required Modifiers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Beginning Oct. 1, the ZC modifier will become effective and applied retroactively to dates of service on or after July 24, 2017, for Renflexis. The table below lists the existing modifiers that should be used to identify the current biosimilar/biological products on the market.

Biosimilar HCPCS Code Product Brand Name Corresponding Required Modifier
Q5102 injection, infliximab, biosimilar, 10 mg Inflectra ZB—Pfizer/Hospira
Q5102 injection, infliximab, biosimilar, 10 mg Renflexis ZC—Merck/Samsung Bioepis

 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For questions or information on coding and billing for these products, contact the ACR Practice Management Department at [email protected].

Filed Under: Biologics & Biosimilars, From the College Tagged With: Biosimilars, Centers for Medicare and Medicaid Services (CMS), Inflectra, Part B modifiers for biosimilars, Renflexis

You Might Also Like:
  • Coding Corner Answer: A Quiz on Modifiers
  • New HCPCS Modifiers Replace -59 on January 1, 2015
  • Coding Corner Question: A Quiz on Modifiers
  • Coding Corner Answers: Billing for Joint Injection within a Series

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)